Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT Pharmacokinetics in Breast Milk and Plasma of Healthy Lactating Women
NCT07257120Phase 4Completed
- Sponsor
- Karuna Therapeutics
- Start
- Jan 2026
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of xanomeline in schizophrenia, sponsored by Karuna Therapeutics. Primary endpoints: Maximum observed concentration of KarXT in Milk, Time of maximum observed concentration of KarXT in Milk and 6 more. Started Jan 2026; status: completed.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07257120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07257120.